ArticleJHEP reports : innovation in hepatology2026
Complementary use of autoantibody detection methods facilitates diagnosis of juvenile autoimmune hepatitis and autoimmune sclerosing cholangitis.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Reply to: "Actin-specific smooth muscle antibodies bridge adult and juvenile autoimmune hepatitis diagnosis".JHEP reports : innovation in hepatology · 2026Article
- Actin-specific smooth muscle antibodies bridge adult and juvenile autoimmune hepatitis diagnosis.JHEP reports : innovation in hepatology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: The diagnosis of juvenile autoimmune hepatitis (AIH) is challenging given its heterogeneous presentation. Autoantibodies, typically detected by immunofluorescence testing (IFT), together with liver histology, represent key diagnostic features. Polyreactive immunoglobulin G (pIgG) has recently emerged as a complementary biomarker in AIH. This retrospective multicentre study aimed to compare ELISA-based autoantibody testing and IFT on HEp-2 cells with the gold standard of IFT on rodent tissue sections in children with autoimmune and non-autoimmune liver diseases. Methods: Autoantibody detection was performed centrally at Hannover Medical School using three commercial antinuclear antibody (ANA) ELISAs, one commercial F-actin ELISA, one in-house pIgG ELISA, and IFT on HEp-2 cells, in comparison to the gold standard of IFT on rodent tissue sections. Samples from children with AIH (n = 69), autoimmune sclerosing cholangitis (AISC; n = 13) and other liver diseases (n = 120) were analysed from nine European centres. Results: The AUCs for the detection of AIH/AISC were moderate to good for ANA detection by IFT (gold standard of rodent tissue AUC: 0.748; HEp-2 AUC: 0.756) and were comparable to ELISA-based detection (0.622-0.772). Anti-smooth muscle antibody (SMA) IFT on rodent tissue yielded an AUC of 0.694. Specificity was increased to 100% by including the SMA staining pattern of vessels, glomeruli and tubules. ELISA-based quantification of anti-F-actin (AUC = 0.868) and pIgG (AUC = 0.844) showed the highest AUCs. While the majority of F-actin-positive children were pIgG-positive (80.3%), pIgG was also detected in 52.4% of F-actin-negative children with AIH. Conclusion: ELISA-based assays provide reliable ANA detection comparable to IFT. Anti-F-actin and pIgG ELISAs showed the highest accuracy for predicting juvenile AIH/AISC and may complement existing diagnostic criteria. Impact and implications: Autoimmune hepatitis (AIH) and autoimmune sclerosing cholangitis (AISC) are rare paediatric liver diseases that can be difficult to distinguish from other hepatopathies. Autoantibody testing is central to diagnosis, yet paediatric performance across platforms has been poorly standardised and sparsely reported. In this multicentre comparison (202 sera from nine expert centres across eight European countries), indirect immunofluorescence (IFT) on rodent tissue showed suboptimal discrimination at the commonly advocated 1:20 cut-off, whereas accuracy for ANA and SMA improved markedly at 1:320. ANA detection by IFT on HEp-2 cells and by ELISA was comparable to rodent tissue IFT. ELISAs for F-actin and pIgG achieved the highest AUCs for identifying AIH/AISC and may complement current diagnostics. Substantial inter-platform discordance for ANA underscores the need for harmonisation. Collectively, these data support the use of multiple validated platforms with platform-appropriate cut-offs in paediatric AIH/AISC serology and support updates to diagnostic algorithms to improve diagnostic timeliness and reliability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.